Skip to main content
Dark area showing tumor against blue background.

TheraSphere™ Y-90 Glass Microspheres

Combination therapies

Stimulate an immune response with TheraSphere1

TheraSphere is a well-tolerated and clinically proven locoregional treatment (LRT) to treat hepatocellular carcinoma (HCC) and has been shown to elicit an immune response.1,2

Y-90 shapes the microenvironment of HCC tumors by inducing tumor cell death and T cell recruitment and activation following therapy.1


Proven + well tolerated

TheraSphere targets the tumor while minimizing impact to surrounding healthy tissue. It safely delivers high-dose radiation directly to the tumor, yielding strong local tumor control. TheraSphere is well-tolerated with minimal side-effects, demonstrating long-term preservation of health-related quality of life (HRQoL).3

icon-liver.

In the LEGACY study, 0% of patients experienced radiation induced liver disease or failure.3

icon-stopwatch

Patients treated with TheraSphere were able to maintain adequate hepatic function for a measurable amount of time to allow for initiation of systemics.4

icon-circle-checkmark

TheraSphere preserves eligibility for future treatment options.5


The ROWAN Study

The ROWAN study is a global, open-label, multi-center, phase II, single-arm study to assess the efficacy of TheraSphere Y-90 Glass Microspheres followed by Durvalumab with Tremelimumab (STRIDE regimen) in patients with hepatocellular carcinoma. ROWAN will explore if there is a benefit of TheraSphere with immunotherapy to improve response for HCC patients.

timeline of Rowan study stages from screening and enrollment to administration of therapies to follow-up.

Collaboration to advance clinical research

With $30+M invested globally, Boston Scientific is actively supporting studies assessing the safety and efficacy of TheraSphere in combination with systemic therapies.

HCC stage focus

early, intermediate and advanced HCC stage focus.

Drug classification targets

drug classification targets PD-1, PD-L1, CTLA-4.

Boston Scientific is supporting studies across multiple stages and drug classification targets.


map pin icon.

Treatment center finder

Instantly locate treatment centers administering TheraSphere near you for your HCC patients.

References

  1. Chew 2018 Hepatology.
  2. Xing et al. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer (2018) 18:7531.
  3. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
  4. Ranganathan S, Gabr A, Entezari P, Riaz A, Desai K, Thornburg B, Kulik L, Kalyan A, Salem R, Lewandowski RJ, Radioembolization for Intermediate Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression, Journal of Vascular and Interventional Radiology (2023).
  5. Atassi et al. Multimodality Imaging Following Y90 Radioembolization: A Comprehensive Review and Pictorial Essay. RadioGraphics, 2008.